As of April 2024 Blueprint Medicines has a market cap of $5.69 Billion. This makes Blueprint Medicines the world's 2405th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $5.69 B | 1.56% |
2023 | $5.60 B | 113.92% |
2022 | $2.62 B | -58.41% |
2021 | $6.30 B | 0.83% |
2020 | $6.25 B | 58.35% |
2019 | $3.94 B | 66.27% |
2018 | $2.37 B | -27.57% |
2017 | $3.27 B | 253.25% |
2016 | $0.92 B | 30.15% |
2015 | $0.71 B |
On Apr 26th, 2024 the market cap of Blueprint Medicines was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Pacific Biosciences
PACB | $0.39 B | -93.08% | ๐บ๐ธ USA |
OPKO Health
OPK | $0.87 B | -84.58% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | $10.93 B | 91.96% | ๐บ๐ธ USA |
Isoray
ISR | $0.10 B | -98.12% | ๐บ๐ธ USA |